With a broad research focus on heart disease risk reduction through the development of novel treatment strategies, Stephen Nicholls, MBBS, PhD, Monash University and Victorian Heart Hospital, ...

In addition to the hypoglycemia and weight gain associated with many treatments for type 2 diabetes, α-glucosidase inhibitors, thiazolidinediones, metformin, sulfonylureas, and the glinides do not ...

There is concern that antidiabetic incretin-based drugs, including dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues, can increase the risk of heart failure.

Collectively, the literature summarized above indicates that glucose homeostasis is governed by a complex interplay among insulin, glucagon, amylin, and incretin hormones. In addition to insulin ...

Reviewed by Loren Wissner Greene, MD, MA (Bioethics), Clinical Associate Professor of Medicine, NYU School of Medicine, New York, NY For many years, it has been well known that causes of type 2 ...

Please provide your email address to receive an email when new articles are posted on . Use of incretin-based therapies after bariatric surgery was linked to a 55% lower risk for new-onset alcohol use ...